Retatrutide's Phase 2a in MASH/MASLD (Sanyal et al., Nat Med 2024) reported approximately 86% relative reduction in liver fat content at 12 mg/week the strongest hepatic-fat data among the incretin class
Clinical Status Human RCT | Observational | Animal | In vitro Primarily studied in preclinical senescence and longevity research models, with no large-scale human clinical trials
Emerging Data on Nerve and Stem Cell Research Some studies imply that GHK-Cu may encourage nerve growth processes through interactions with growth factor expression
Fernando Gallardo has received fees as presenter, consultant, and support for attendance of course and congresses and/or investigation projects in the following companies: Janssen, Abbvie, UCB, Amgen, Bristol, Lilly, Novartis, Almirall, Leo Pharma
For example, metalloproteinase inhibitor 4 (TIMP4) was upregulated by semaglutide in STEP 2 but not STEP 1
We are working with a new pharmacy that still has some remaining supplies